MetaADEDB 2.0 @ LMMD
nitisinone
(OUBCNLGXQFSTLU-UHFFFAOYSA-N)
Structure
SMILES
O=C1CCCC(=O)C1C(=O)c1ccc(cc1[N+](=O)[O-])C(F)(F)F
Type(s)
Approved; Investigational
ATC code(s)
A16AX04
Molecular Formula:
C14H10F3NO5
Molecular Weight:
329.228
Log P:
3.2578
Hydrogen Bond Acceptor:
3
Hydrogen Bond Donor:
0
TPSA:
97.03
CAS Number(s):
104206-65-7
Synonym(s)
1.
nitisinone
2.
2-(2-nitro-4-(trifluoromethyl)benzoyl)cyclohexane-1,3-dione
3.
2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
4.
NTBC cpd
5.
Orfadin
External Link(s)
MeSHC077073
PubChem Compound115355
BindingDB50088804
ChEBI50378
CHEMBLCHEMBL1337
DrugBankDB00348
DrugCentral1944
IUPHAR/BPS Guide to PHARMACOLOGY6834
KEGGdr:D05177
Therapeutic Target DatabaseD0V1UW
ZINC100014475
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Amino acid level increasedFAERS: 55OFFSIDES
US FAERS
2Succinylacetone increasedFAERS: 25US FAERS
3Amino acid level decreasedFAERS: 21US FAERS
4Drug ineffectiveFAERS: 13OFFSIDES
US FAERS
5VomitingFAERS: 13US FAERS
6EpilepsyFAERS: 10US FAERS
7Abdominal PainFAERS: 8US FAERS
8PainFAERS: 8US FAERS
9SepsisFAERS: 8US FAERS
10AscitesFAERS: 7OFFSIDES
US FAERS
11General physical health deteriorationFAERS: 7US FAERS
12Intellectual DisabilityFAERS: 7US FAERS
13Mental impairmentFAERS: 7US FAERS
14DehydrationFAERS: 6US FAERS
15Drug level decreasedFAERS: 6US FAERS
16Respiratory distressFAERS: 6US FAERS
17BronchitisFAERS: 5OFFSIDES
US FAERS
18Disease ProgressionFAERS: 5US FAERS
19DizzinessFAERS: 5US FAERS
20Educational problemFAERS: 5OFFSIDES
US FAERS
21Eye painFAERS: 5OFFSIDES
US FAERS
22Hepatic EncephalopathyFAERS: 5US FAERS
23KeratitisFAERS: 5US FAERS
24PneumoniaFAERS: 5US FAERS
25Product supply issueFAERS: 5US FAERS
26Blood creatine phosphokinase increasedFAERS: 4US FAERS
27Chest PainFAERS: 4US FAERS
28Cytolytic hepatitisFAERS: 4OFFSIDES
US FAERS
29HepatomegalyFAERS: 4US FAERS
30MalnutritionFAERS: 4US FAERS
31Memory impairmentFAERS: 4US FAERS
32Mental RetardationFAERS: 4OFFSIDES
US FAERS
33Portal HypertensionFAERS: 4OFFSIDES
US FAERS
34PriapismFAERS: 4US FAERS
35nervous system disorderFAERS: 4US FAERS
36AnxietyFAERS: 3US FAERS
37AppendicitisFAERS: 3OFFSIDES
US FAERS
38Aspartate Aminotransferase IncreasedFAERS: 3US FAERS
39DeafnessFAERS: 3US FAERS
40Drug dose omissionFAERS: 3US FAERS
41EczemaFAERS: 3US FAERS
42Eye irritationFAERS: 3US FAERS
43HeadacheFAERS: 3US FAERS
44HepatoblastomaFAERS: 3OFFSIDES
US FAERS
45MalaiseFAERS: 3US FAERS
46Malignant neoplasm progressionFAERS: 3US FAERS
47Maternal exposure during pregnancyFAERS: 3US FAERS
48Metabolic acidosisFAERS: 3US FAERS
49MicrocephalyFAERS: 3OFFSIDES
US FAERS
50OpisthotonusFAERS: 3OFFSIDES
US FAERS
51PhotophobiaFAERS: 3US FAERS
52PregnancyFAERS: 3US FAERS
53Psychomotor skills impairedFAERS: 3US FAERS
54QuadriparesisFAERS: 3OFFSIDES
US FAERS
55Suicide attemptFAERS: 3US FAERS
56ThrombocytopeniaFAERS: 3US FAERS
57Urine delta aminolevulinate increasedFAERS: 3OFFSIDES
US FAERS
58Alanine Aminotransferase IncreasedFAERS: 2US FAERS
59AngerFAERS: 2OFFSIDES
US FAERS
60AstheniaFAERS: 2US FAERS
61BronchiolitisFAERS: 2US FAERS
62Cardiac ArrestFAERS: 2US FAERS
63CholestasisFAERS: 2US FAERS
64ConstipationFAERS: 2US FAERS
65Corneal lesionFAERS: 2US FAERS
66CyanosisFAERS: 2OFFSIDES
US FAERS
67Deposit eyeFAERS: 2US FAERS
68Drug toxicityFAERS: 2OFFSIDES
US FAERS
69EclampsiaFAERS: 2US FAERS
70Economic problemFAERS: 2US FAERS
71Eye RednessFAERS: 2OFFSIDES
US FAERS
72Eye inflammationFAERS: 2US FAERS
73Failure to ThriveFAERS: 2US FAERS
74FatigueFAERS: 2US FAERS
75Feeling abnormalFAERS: 2US FAERS
76Glioblastoma MultiformeFAERS: 2US FAERS
77Guillain-Barre SyndromeFAERS: 2US FAERS
78HepatitisFAERS: 2US FAERS
79HepatosplenomegalyFAERS: 2OFFSIDES
US FAERS
80InfectionFAERS: 2US FAERS
81InfluenzaFAERS: 2US FAERS
82LymphomaFAERS: 2OFFSIDES
US FAERS
83Metastases to adrenalsFAERS: 2US FAERS
84MutismFAERS: 2US FAERS
85MyoclonusFAERS: 2US FAERS
86NauseaFAERS: 2US FAERS
87NephrolithiasisFAERS: 2US FAERS
88ObesityFAERS: 2US FAERS
89PolyneuropathyFAERS: 2OFFSIDES
US FAERS
90Protein total decreasedFAERS: 2OFFSIDES
US FAERS
91Protein total increasedFAERS: 2US FAERS
92PruritusFAERS: 2US FAERS
93Respiratory FailureFAERS: 2US FAERS
94SyncopeFAERS: 2US FAERS
95TachycardiaFAERS: 2US FAERS
96Urinary tract infectionFAERS: 2US FAERS
97Urine delta aminolevulinateFAERS: 2US FAERS
98jaundiceFAERS: 2US FAERS
99AbasiaFAERS: 1OFFSIDES
US FAERS
100Accidental deathFAERS: 1US FAERS
101AcidosisFAERS: 1US FAERS
102Acrodermatitis enteropathicaFAERS: 1US FAERS
103Acute kidney injuryFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
104AdenoidectomyFAERS: 1US FAERS
105AneurysmFAERS: 1US FAERS
106Back PainFAERS: 1US FAERS
107BlepharitisFAERS: 1US FAERS
108Blood alkaline phosphatase increasedFAERS: 1US FAERS
109Blood sodium decreasedFAERS: 1US FAERS
110Body height below normalFAERS: 1US FAERS
111Bronchopulmonary DysplasiaFAERS: 1US FAERS
112Burning sensationFAERS: 1US FAERS
113Cell DeathFAERS: 1US FAERS
114CholelithiasisFAERS: 1US FAERS
115Coagulation test abnormalFAERS: 1US FAERS
116ConjunctivitisFAERS: 1US FAERS
117Corneal OpacityFAERS: 1US FAERS
118Corneal erosionFAERS: 1US FAERS
119Death of relativeFAERS: 1US FAERS
120Depressed Level of ConsciousnessFAERS: 1US FAERS
121Device related sepsisFAERS: 1US FAERS
122Disseminated Intravascular CoagulationFAERS: 1US FAERS
123DrowningFAERS: 1US FAERS
124Dry skinFAERS: 1OFFSIDES
US FAERS
125DysphoniaFAERS: 1US FAERS
126Ear tube insertionFAERS: 1US FAERS
127Electroencephalogram abnormalFAERS: 1US FAERS
128ErythemaFAERS: 1US FAERS
129Facial PainFAERS: 1US FAERS
130GastritisFAERS: 1US FAERS
131GastroenteritisFAERS: 1OFFSIDES
US FAERS
132General physical condition abnormalFAERS: 1US FAERS
133Genital erythemaFAERS: 1US FAERS
134GlaucomaFAERS: 1US FAERS
135Hepatic dysplasiaFAERS: 1OFFSIDES
US FAERS
136HyperphagiaFAERS: 1US FAERS
137HypersensitivityFAERS: 1US FAERS
138HypophagiaFAERS: 1US FAERS
139HypothyroidismFAERS: 1US FAERS
140IleusFAERS: 1US FAERS
141Incorrect dose administeredFAERS: 1US FAERS
142Infantile spitting upFAERS: 1US FAERS
143InflammationFAERS: 1US FAERS
144Intelligence test abnormalFAERS: 1US FAERS
145Intestinal ObstructionFAERS: 1OFFSIDES
US FAERS
146LethargyFAERS: 1US FAERS
147Liver transplant rejectionFAERS: 1US FAERS
148LymphadenopathyFAERS: 1US FAERS
149Malignant transformationFAERS: 1US FAERS
150Medication ErrorFAERS: 1US FAERS
151Mental status changesFAERS: 1US FAERS
152Metastases to muscleFAERS: 1US FAERS
153Myoclonic EpilepsyFAERS: 1US FAERS
154MyopathyFAERS: 1US FAERS
155Neonatal disorderFAERS: 1US FAERS
156NeuroblastomaFAERS: 1US FAERS
157Nutritional condition abnormalFAERS: 1US FAERS
158Oropharyngeal painFAERS: 1US FAERS
159OverweightFAERS: 1US FAERS
160ParesisFAERS: 1US FAERS
161PeritonitisFAERS: 1US FAERS
162PiloerectionFAERS: 1US FAERS
163PingueculaFAERS: 1US FAERS
164Pneumococcal sepsisFAERS: 1US FAERS
165Posterior reversible encephalopathy syndromeFAERS: 1US FAERS
166Protein total abnormalFAERS: 1US FAERS
167Prothrombin level decreasedFAERS: 1US FAERS
168Prothrombin time ratio decreasedFAERS: 1US FAERS
169PseudoporphyriaFAERS: 1US FAERS
170Rash erythematousFAERS: 1US FAERS
171Renal tubular disorderFAERS: 1US FAERS
172Respiratory arrestFAERS: 1US FAERS
173Respiratory muscle weaknessFAERS: 1US FAERS
174Respiratory tract congestionFAERS: 1US FAERS
175RicketsFAERS: 1US FAERS
176Selective MutismFAERS: 1US FAERS
177Sensory level abnormalFAERS: 1US FAERS
178Septic ShockFAERS: 1US FAERS
179Speech rehabilitationFAERS: 1US FAERS
180Subcutaneous AbscessFAERS: 1US FAERS
181TenosynovitisFAERS: 1
Canada Vigilance: 1
Canada Vigilance
US FAERS
182Therapy cessationFAERS: 1US FAERS
183Therapy non-responderFAERS: 1US FAERS
184TonsillectomyFAERS: 1US FAERS
185Transaminases increasedFAERS: 1US FAERS
186Ultrasound liver abnormalFAERS: 1US FAERS
187Visual ImpairmentFAERS: 1US FAERS
188Weight decreasedFAERS: 1US FAERS
189Zinc deficiencyFAERS: 1US FAERS
190treatment failureFAERS: 1US FAERS
191Acute polyneuropathyOFFSIDES
192AmnesiaOFFSIDES
193ApneaOFFSIDES
194Bulbar palsyOFFSIDES
195Cardioactive drug levelOFFSIDES
196CirrhosisOFFSIDES
197Conjunctival depositOFFSIDES
198DiarrheaOFFSIDES
199Fluid overloadOFFSIDES
200HyporeflexiaOFFSIDES
201Neonatal hypotensionOFFSIDES
202Neonatal respiratory failureOFFSIDES
203Tyrosinemias11488774
12899938
CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120240

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.